Photo from academic.microsoft.com
Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for… Click to show full abstract
Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU‐mediated anti‐obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor‐selective agonists.
Keywords:
selective agonists;
differential effects;
neuromedin receptors;
receptors obese;
effects selective;
agonists neuromedin
Journal Title: British Journal of Pharmacology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Pharmacology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!